Today
July 25, 2026Dilution Risk
1Last 7DListing Risk
37Last 30DEarnings
8Last 7DInsider / Ownership
3Last 14DDividends
1Last 30DFDA / Clinical
13Last 30DN/AN/A+0.00%
Insider / Ownership
Corvex Management LP proposes sale of $63.48M
Corvex proposes to sell 400,000 Illumina shares, about $63.5M, on or about May 29, 2026.
bearishImpact 70
LINDN/A+0.00%
Insider / Ownership
Director Mark Ein proposes to sell 300,000 shares
Director Mark Ein proposes to sell 300,000 LIND shares worth about $6.9M.
bearishImpact 54
SIONN/A+0.00%
Insider / Ownership
OrbiMed Private Investments VIII, LP proposes to sell 1,082,480 shares
OrbiMed proposes to sell 1,082,480 SION shares for about $46.3M.
bearishImpact 66
N/AN/A+0.00%
Insider / Ownership
Officer Althoff Judson proposes sale of $7.15M
Officer Althoff Judson proposes to sell 15,500 Microsoft shares for about $7.15M.
bearishImpact 52
N/AN/A+0.00%
Insider / Ownership
Officer Jason E Long proposes to sell 1,417 shares, about 14% of shares outstanding
Officer Jason E Long proposes to sell 1,417 shares (~$104k), about 14% of outstanding.
bearishImpact 60
NXTN/A+0.00%
Insider / Ownership
Officer-director Daniel S. Shugar proposes sale of 55,000 shares
Officer-director Daniel S. Shugar proposes to sell 55,000 Class A shares (~$8.35M).
bearishImpact 68
SNOWN/A+0.00%
Insider / Ownership
Director Frank Slootman proposes to sell 162,924 shares
Director Slootman proposes sale of 162,924 shares (~$43M).
bearishImpact 68
ANFN/A+0.00%
Earnings
Q1 FY2026 results: record net sales; EPS $1.47; maintains full-year guidance and share-repurchase plan
Abercrombie & Fitch reported record Q1 net sales ($1.1B) and EPS of $1.47 that exceeded its outlook, maintained FY guidance and signaled sizable share repurchases — indicating continued operational momentum despite regional softness in EMEA.
bullishImpact 80
BLRXN/A+0.00%
Earnings
BioLineRx reports Q1 2026 results; going-concern disclosed
BioLineRx reported Q1 2026 results and attached interim financials and an operating review that include a going-concern disclosure (accumulated losses of $403M). Company progress on GLIX1 (first patient dosed) is a positive development, but the going-concern and ongoing cash burn raise near-term financial risk.
bearishImpact 80
TDACN/A+0.00%
Strategic Transaction
TDAC enters Business Combination Agreement to merge with ProLogium
TDAC announced a Business Combination Agreement to merge with ProLogium (dated May 27, 2026). The filing includes the merger agreement and related voting/lock‑up/registration exhibits, an implied equity value (~$3.8B), warrant terms ($11.50 exercise), and Available Cash and closing/deadline mechanics — a de‑SPAC transaction that will require shareholder approvals and affects listing, dilution and timing.
volatileImpact 80
ABCDN/A+0.00%
Shareholder Vote
Shareholders Asked to Vote on Reverse Split and Share Increase
Vote is pending; 3 proposals need result and post-meeting implementation checks.
bearishImpact 72
DIVCN/A+0.00%
Dividends
$0.25 Quarterly Cash Dividend Declared
The board declared a routine quarterly dividend with record and payment dates disclosed.
neutralImpact 62
ORBNN/A+0.00%
IPO / Listing
Orion BioSystems Sets IPO Range Ahead of Nasdaq Listing
The IPO range is set, with SEC effectiveness and final pricing still ahead.
neutralImpact 72
ABSPN/A+0.00%
Strategic Transaction
SPAC Redemption Leaves De-SPAC Closing Risk in Focus
Vote approved, but redemptions leave minimum cash and liquidity as the main closing variables.
volatileImpact 74
N/AN/A+0.00%
IPO / Listing
Luvulis files S‑1/A to offer 4.5M shares at $0.0225; auditor flags going concern
Registers 4.5M shares at $0.0225; auditor cites going‑concern.
bearishImpact 62
RIMEN/A+0.00%
Dilution Risk
Resale registration for up to 10M shares; auditors flag going-concern
Algorhythm registered 10,000,000 resale shares while auditors cite substantial doubt about going concern.
bearishImpact 80
EAXRN/A+0.00%
Dilution Risk
Resale registration: 22.6M Ealixir shares; auditor flagged going concern
Company registered 22.6M shares for resale; auditor issued going-concern opinion.
bearishImpact 78
BDMDN/A+0.00%
Dilution Risk
Registration of up to 34.4M resale shares and 11.5M warrant shares
F-3 conversion registers large resale and warrant share overhang that may pressure BDMD shares.
bearishImpact 75
CANN/A+0.00%
Dilution Risk
Canaan files post-effective shelf amendment registering $270M
Registers $270M shelf for potential future securities issuances.
bearishImpact 52
SPWRN/A+0.00%
Dilution Risk
Post-effective S-1 amendment registers 48.5M shares for White Lion resale
SunPower registered 48.5M shares for resale under an equity line, enabling potential dilution.
bearishImpact 60